A Crisis in the Treatment of Osteoporosis

Journal of Bone and Mineral Research

Volumn 31, Issue 8, 2016, Pages 1485-1487

  Khosla, Sundeep ^a   Shane, Elizabeth ^b  

^a Mayo Clinic College of Medicine   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ODANACATIB; ROMOSOZUMAB;

ATRIAL FIBRILLATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FEMUR FRACTURE; FRACTURE; HIP FRACTURE; HOSPITAL DISCHARGE; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; RECURRENT DISEASE; RISK FACTOR; TREATMENT INDICATION;

EID: 84980010280     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2888     Document Type: Editorial

References (13)

1. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49:2–19.
2. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016; 374:254–62.
3. Kolata G. Fearing rare side effects, millions take their chances with osteoporosis. New York Times [Internet]. 2016 Jun 1 [cited 2016 Jun 22]. Available from: http://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html?_r=0.
4. Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015 30:2179–87.
5. Kim SC, Kim DH, Mogun H, et al. Impact of the U.S. Food and Drug Administration's safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res. Forthcoming. Epub 2016 Mar 31. DOI: 10.1002/jbmr.2832.
6. Eisman JA, Bogoch ER, Dell R, et al.; ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR Task Force on Secondary Fracture Prevention. J Bone Miner Res. 2012; 27:2039–46.
7. Modi A, Siris ES, Tang J, Sen S. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin. 2015; 31:757–65.
8. Selga J, Nunez JH, Minguell J, Lalanca M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int. 2016; 27:827–32.
9. Amgen. Amgen and UCB announce positive top-line results from the phase 3 study of romosozumab in postmenopausal women with osteoporosis. PR Newswire [Internet]. 2016 Feb 22 [cited 2016 Jun 22]. Available from: http://www.prnewswire.com/news-releases/amgen-and-ucb-announce-positive-top-line-results-from-the-phase-3-study-of-romosozumab-in-postmenopausal-women-with-osteoporosis-300223526.html.
10. Merck. Merck announces data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis. Merck News Release [Internet]. Whitehouse Station, NJ: Merck; 2014 Sep 15 [cited 2016 Jun 22]. Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st.
11. Spiegel A. How a bone disease grew to fit the prescription [Internet]. Washington, DC: National Public Radio (NPR); 2009 Dec 21 [cited 2016 Jun 22]. Available from: http://www.npr.org/2009/12/21/121609815/how-a-bone-disease-grew-to-fit-the-prescription.
12. Black DM, Kelly MP, Genant HK, et al.; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362:1761–71.
13. Taylor F, Huffman M, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816. DOI: 10.1002/14651858.CD004816.pub5.